Saga Lifesciences Limited

Saga Lifesciences Limited, established on July 10, 2019, is a public limited company headquartered in Ahmedabad, Gujarat, India. The company is registered under the Corporate Identification Number (CIN) U24239GJ2019PLC109035. With an authorized and paid-up capital of ₹10 million, Saga Lifesciences has demonstrated consistent growth since its inception. The company employs approximately 221 professionals, reflecting its expanding operations. Its manufacturing facility spans over 11,000 square meters and adheres to global Good Manufacturing Practices (GMP), holding certifications from international regulatory bodies such as the European Union (EU) GMP, Therapeutic Goods Administration (TGA) Australia, Health Canada, and the World Health Organization (WHO) GMP. Saga Lifesciences exports its products to over 40 countries, including regions in Europe, Asia, Latin America, Africa, and Canada, underscoring its significant global footprint.

Saga Lifesciences operates a state-of-the-art manufacturing facility located in Ahmedabad, Gujarat, India. The plant covers an area exceeding 11,000 square meters and is compliant with international GMP standards. It has been approved by several international regulators, including the EU GMP, TGA Australia, Health Canada, and WHO GMP. The facility specializes in the production of a diverse range of finished pharmaceutical formulations, including tablets, capsules, dry syrups, oral powders, liquids, injections, and ointments. This extensive product portfolio caters to both general formulations and specialized segments such as cephalosporins. The plant's capacity and capabilities enable Saga Lifesciences to meet the demands of various international markets effectively.

The leadership team at Saga Lifesciences Limited comprises several key individuals:

• Viranchi Arvindbhai Shah: Director
• Vinit Arvindbhai Shah: Director
• Rushabh Vinit Shah: Director
• Ruchir Vinitbhai Shah: Director
• Vishal Harilal Haswani: Director
• Sanjaykumar Jasvantlal Shah: Director

These directors collectively oversee the strategic direction and operational management of the company, contributing to its growth and expansion in the pharmaceutical industry.

Saga Lifesciences Limited has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility holds certifications from international regulatory bodies such as the EU GMP, TGA Australia, Health Canada, and WHO GMP, facilitating access to these markets. Additionally, Saga Lifesciences has dedicated offices and marketing teams in Australia, Vietnam, Ghana, and Latin America, indicating a strategic approach to market penetration and regulatory compliance in these regions.

Saga Lifesciences Limited has expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's global partnerships include dedicated offices in Australia, Vietnam, Ghana, and Latin America, with a focus on regions such as Honduras and Venezuela. These strategic expansions enable Saga Lifesciences to leverage the World Health Organization's (WHO) prequalification program, enhancing access to these markets and reinforcing its commitment to providing quality pharmaceutical products globally.

Saga Lifesciences Limited has adopted a diversified geographic strategy, establishing a presence in over 40 countries across Europe, Asia, Latin America, Africa, and Canada. This broad market reach mitigates concentration risk and positions the company to capitalize on growth opportunities in various regions. The establishment of dedicated offices and marketing teams in Australia, Vietnam, Ghana, and Latin America further demonstrates Saga Lifesciences' commitment to localized market engagement and strategic expansion.

Saga Lifesciences Limited's manufacturing facility is registered with the U.S. Food and Drug Administration (FDA), indicating compliance with FDA regulations for pharmaceutical manufacturing. The company has filed Abbreviated New Drug Applications (ANDAs) for its products, facilitating market access in the United States. While specific details regarding Drug Master File (DMF) filings and inspection history are not publicly disclosed, the FDA registration and ANDA filings suggest adherence to FDA standards and a commitment to maintaining product quality and safety.

Saga Lifesciences Limited's manufacturing facility holds certifications from the World Health Organization (WHO) Good Manufacturing Practices (GMP) and the European Union (EU) GMP. These certifications attest to the company's adherence to international quality standards and regulatory requirements, ensuring that its products meet the stringent criteria set by these organizations. The WHO GMP certification, in particular, facilitates access to markets in developing countries, while the EU GMP certification is essential for trade within the European Union.

Saga Lifesciences Limited operates in compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations in India. The company's manufacturing facility holds the necessary licenses from the CDSCO, ensuring adherence to national standards for pharmaceutical manufacturing. Additionally, Saga Lifesciences has obtained export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), facilitating the export of its products to various international markets.

As of March 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Saga Lifesciences Limited by regulatory authorities such as the FDA. This absence suggests that the company maintains a strong compliance record and adheres to regulatory standards in its manufacturing and export operations.

Saga Lifesciences Limited operates in a competitive pharmaceutical industry, with numerous companies offering similar product portfolios. While specific market share data for Saga Lifesciences' competitors is not publicly available, the company's diverse product range and international certifications position it favorably in the market. The establishment of dedicated offices and marketing teams in key regions, such as Australia, Vietnam, Ghana, and Latin America, indicates a strategic approach to market penetration and competitive positioning.

Saga Lifesciences Limited distinguishes itself through its ultramodern manufacturing facility, which complies with international GMP standards and holds certifications from regulatory bodies such as the EU GMP, TGA Australia, Health Canada, and WHO GMP. The company's extensive and diverse product portfolio, encompassing solid oral dosage forms, liquids, injections, and ointments, caters to a wide range of therapeutic needs. Additionally, Saga Lifesciences' in-house formulation and development wing enables the company to develop advanced formulations bio-equivalent to innovator drugs, enhancing its competitive edge.

Saga Lifesciences Limited has positioned itself as a vertically integrated pharmaceutical company, engaging in formulation development, manufacturing, and marketing. The company's strategic direction focuses on expanding its global footprint by exporting products to over 40 countries and establishing dedicated offices in regions such as Australia, Vietnam, Ghana, and Latin America. This approach underscores Saga Lifesciences' commitment to providing quality pharmaceutical products worldwide and its dedication to meeting the diverse needs of healthcare professionals and patients.

Saga Lifesciences Limited has demonstrated a strong track record in pharmaceutical manufacturing, with an estimated annual revenue of $19.6 million and a consistent year-over-year growth rate of 30% since its inception. The company's manufacturing facility is certified by international regulatory bodies, including the EU GMP, TGA Australia, Health Canada, and WHO GMP, indicating a high level of reliability and adherence to global quality standards. Additionally, Saga Lifesciences has commercialized and registered over 200 products successfully, reflecting its capability and consistency in delivering quality pharmaceutical formulations.

Importers should verify the following certifications to ensure the quality and compliance of Saga Lifesciences Limited's products:

• FDA Registration: Confirm the company's registration with the U.S. Food and Drug Administration (FDA) to ensure compliance with U.S. regulations.

• WHO GMP Certification: Verify the World Health Organization's Good Manufacturing Practices certification to ensure adherence to international